Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 810 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle (placebo) Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction

NCT05261386
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
CBT-008
Drug
Lead sponsor
Cloudbreak Therapeutics, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis

NCT02618759
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DSXS, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Phase 2 Interventional

Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris

NCT03322137
View directory record Official record
Conditions
Pruritus, Psoriasis Vulgaris
Interventions
SNA-120, Vehicle
Drug
Lead sponsor
Sienna Biopharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
38
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 2, 2026, 5:25 AM EDT
Completed No phase listed Observational

Nutrition Blood Outcomes Following Tocotrienol N2B

NCT01858311
View directory record Official record
Conditions
Stroke
Interventions
Tocotrienol Capsules, Placebo Vehicle
Dietary Supplement · Other
Lead sponsor
Ohio State University
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection

NCT04766931
View directory record Official record
Conditions
Covid19
Interventions
FB2001, FB2001 Placebo
Drug
Lead sponsor
Frontier Biotechnologies Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 2, 2026, 5:25 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

NCT05389267
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Kinezodianone R hydrochloride, Placebo
Drug
Lead sponsor
Laboratoires Thea
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of BRM421 for Dry Eye Syndrome

NCT03066219
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
BRM421, Placebo
Drug
Lead sponsor
BRIM Biotechnology Inc.
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Lewiston, Maine • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

Oral Peanut Immunotherapy

NCT01324401
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut flour OIT
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 2, 2026, 5:25 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects

NCT01602328
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
AC607, Vehicle Only
Biological
Lead sponsor
AlloCure Inc.
Industry
Eligibility
21 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • San Diego, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

NCT01915823
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
azelastine hydrochloride and fluticasone propionate, Dymista vehicle
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
4 Years to 11 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Alaska • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Assessment of LBR-101 In Chronic Migraine

NCT02021773
View directory record Official record
Conditions
Chronic Migraine
Interventions
LBR-101 High Dose, LBR-101 Low Dose, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
57
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

CP-690-550 Ointment For Chronic Plaque Psoriasis

NCT01246583
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550 Ointment 1, Vehicle 1, CP-690,550 Ointment 2, Vehicle 2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Mobile, Alabama • Los Angeles, California • Orange Park, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of RM-493 on Energy Expenditure in Obese Individuals

NCT01867437
View directory record Official record
Conditions
Obesity, Morbid Obesity
Interventions
Placebo, RM-493
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Phase 3 Interventional

Phase 3 Study of EBI-005 in Dry Eye Disease

NCT01998802
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
Active Comparator EBI-005, Placebo Comparator
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
45
States / cities
Chandler, Arizona • Mesa, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Phase 1 Interventional

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT03261739
View directory record Official record
Conditions
NAFLD
Interventions
RYI-018, Placebo
Biological
Lead sponsor
Bird Rock Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon

NCT02688270
View directory record Official record
Conditions
Raynaud's Phenomenon Secondary to Connective Tissue Disease
Interventions
Vascana (0.9% nitroglycerin cream), Vehicle Cream (placebo)
Drug
Lead sponsor
Covis Pharma S.à.r.l.
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Multiple Locations, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers

NCT01518699
View directory record Official record
Conditions
Pediculosis
Interventions
Ha44, Ha44 Placebo, Moxifloxacin Placebo, Moxifloxacin
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects

NCT01068158
View directory record Official record
Conditions
Head Lice
Interventions
0.5% Ivermectin Cream, Placebo control
Drug
Lead sponsor
Topaz Pharmaceuticals Inc
Industry
Eligibility
5 Months and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
7
States / cities
Little Rock, Arkansas • Delray Beach, Florida • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

NCT04284514
View directory record Official record
Conditions
Ocular Hypertension, Primary Open Angle Glaucoma
Interventions
AKB-9778 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Aerpio Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Austin, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 2, 2026, 5:25 AM EDT
Recruiting Phase 2 Interventional

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

NCT05639933
View directory record Official record
Conditions
Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
Interventions
HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel, HT-001 Placebo
Drug
Lead sponsor
Hoth Therapeutics, Inc.
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Irvine, California • Orange, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

NCT00916006
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 Gel, Vehicle gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Los Angeles, California • Oceanside, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Study of AP0302 5% Versus a Vehicle Comparator

NCT02324985
View directory record Official record
Conditions
Pain, Delayed Onset Muscle Soreness
Interventions
S-Ibuprofen Topical Gel 5%, Vehicle Topical Gel
Drug
Lead sponsor
Aponia Laboratories, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 2, 2026, 5:25 AM EDT
Terminated Not applicable Interventional Results available

Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia

NCT02144155
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin: 24IU - 168 IU, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 2, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Cantharidin in Molluscum Contagiosum

NCT00667225
View directory record Official record
Conditions
Molluscum Contagiosum, Skin Disease
Interventions
cantharidin's vehicle, Cantharidin 0.7%
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
5 Years to 10 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Oct 2, 2026, 5:25 AM EDT